Context: Müllerian-inhibiting substance/anti-Müllerian hormone (MIS/AMH) is produced in the ovarian granulosa cells, and it is believed to inhibit ovarian folliculogenesis and steroidogenesis in women of reproductive age.
M¨u llerian-inhibiting substance (MIS), also called anti-Müllerian hormone (AMH), is a member of the TGF-b superfamily of growth and differentiation response modifiers. MIS/AMH is produced in immature Sertoli cells in fetal testes and binds to its receptors in primordial Müllerian ducts to cause regression of female reproductive structures that are the precursors to the Fallopian tubes, uterus, cervix, upper third of the vagina, and surface epithelium of the ovaries (1, 2) . The physiological concentrations of MIS/AMH in women are 2 to 5 ng/mL in serum and follicular fluid, and it is believed to be involved in the reproductive endocrine development, such as the initial follicular recruitment, follicular development and atresia, oocyte maturation, and steroidogenesis in granulosa cells (3, 4) .
MIS/AMH receptors (MISR/AMHR), like other members of the TGF-b family of receptors, are heteromeric complexes consisting of type I and type II transmembrane serine/threonine kinase receptors. Therefore, the C-terminal dimer of MIS/AMH most likely binds the extracellular cysteine-rich domain of MISR/AMHR type II (MISRII/AMHRII), which subsequently phosphorylates MISRI/AMHRI to trigger downstream signal transduction (5, 6) .
Previous studies showed that MISRII/AMHRII mRNA is expressed mainly in the granulosa cells of preantral and small antral follicles in adult rat ovaries. Large antral follicles and corpus luteum express little or no MISRII/AMHRII mRNA, and primordial follicles, oocytes, theca, and interstitial cells and atretic follicles appeared to be MISRII/AMHRII mRNA negative (7, 8) . However, the specific MISRII/AMHRII can be detected in theca cells of small growing follicles (9, 10) . Ingraham et al. (9) reported the expression of MISRII/AMHRII in theca cells of the preantral and small antral follicles of adult rat ovaries, but unlike the granulosa cell expression, theca cells continue to express MISRII/AMHRII in antral and early atretic follicles. This pattern for expression of the MISRII/AMHRII in follicles and several studies regarding expression of MIS/AMH and MISRII/AMHRII could suggest a potential regulatory function of MIS/ AMH in folliculogenesis and steroidogenesis (4, 5, 9, 11) .
Therefore, the purpose of this study was to assess the expression of MISRII/AMHRII in the granulosa and theca cell compartments and to identify the exact targets of MIS/AMH produced in the granulosa cells.
Materials and Methods

Study participants
Normal ovarian tissue samples were collected from 25 patients who underwent partial or complete surgical resection of the ovaries. Six patients diagnosed with benign ovarian teratoma, nine patients with benign ovarian cystadenoma, eight patients with endometriosis, and the samples obtained from two breast cancer patients who underwent bilateral ovarian resection were enrolled in this study. The mean age of the patients was 37.5 6 4.8 years, and the mean body mass index was 23.7 6 0.5 kg/m 2 . All patients had ovulatory menstrual cycle, and their serum estradiol and follicle-stimulating hormone (FSH) level were within normal range. They did not use any hormonal agents, such as oral contraceptives or gonadotropinreleasing hormone analogs. In breast cancer patients, surgery was done before starting antiestrogen drugs. This study was approved by the Institutional Review Board of the Seoul St. Mary's Hospital (#KC12TISI0435), and written, informed consent, especially about the removal of the remained normal ovarian tissue just beside pathologic tissue during the surgery, was obtained before the operation from all patients.
Tissue preparation
The tissues samples were dissected into several slices. Some ovarian tissues were used for laser microdissection, and the others were fixed in 4% paraformaldehyde solution overnight at 4°C before production of 50 mm-thick vibratome sections or 5 mm-thick wax sections for morphological methods.
Laser microdissection
Fresh ovarian tissues from three patients (one ovarian teratoma, one benign ovarian cystadenoma, and one endometriosis), embedded using optimal cutting temperature medium (Sakura Finetek USA, Torrance, CA), were rapidly frozen and stored in liquid nitrogen. With the use of a cryostat microtome (Leica CM1850; Leica, Wetzlar, Germany), frozen 10 mm-thick sections were prepared and mounted on the window slides (1.4 mm thick, with supporting membrane). Following the fixation in 100% isopropyl alcohol at 4°C, the sections were stained with 0.2% toluidine blue (MilliporeSigma, St. Louis, MO)-0.1% eosin (MilliporeSigma) dye in 70% isopropyl alcohol for 30 seconds. Afterward, the sections were dehydrated with 100% isopropyl alcohol, three times, and fixed in xylene until the microdissection. After identification of the glassy membrane of the granulosa layer, the air-dried sections were microdissected into granulosa and theca cell layers using an image-oriented navigation laser microdissection device (JungWoo International, Seoul, South Korea; Fig. 1 ). Three areas were microdissected for each sample.
RT-PCR
RNA extraction and RT
Microdissected granulosa and theca cell layers were separately homogenized using Trizol reagent (Thermo Fisher Scientific, Waltham, MA). Chloroform was added to the homogenized samples, and they were centrifuged at 13,000 rpm for 20 minutes at 4°C. The aqueous phase was collected by careful pipetting and placed in a new tube. To obtain the RNA precipitate, isopropanol was added, together with 2 mL glycogen, and the samples were incubated for 10 minutes at room temperature and then recentrifuged at 13,000 rpm for 10 minutes at 4°C. After removing the supernatant, the pellet was washed with 75% ethanol and dissolved in 15 mL RNase-free water, and RNA concentration was measured. Testis and liver tissues, for positive and negative controls, respectively, were processed with the same method to extract the RNAs.
To synthesize cDNA, RT was performed using the cDNA Synthesis Kit (Takara Korea Biomedical, Seoul, South Korea). Four microliters of five times RT buffer, 1 mL Moloney murine leukemia virus RT, 1 mL deoxyribonucleotide triphosphate mix, 1.5 mL random primer mix, 1.5 mL oligo(dT), 1 mL RNase inhibitor, 2 mg isolated RNA, and diethylpyrocarbonate-treated deionized water were added to a total volume of 20 mL, which was incubated for 10 minutes at 25°C, 60 minutes at 42°C, and 10 minutes at 70°C, using a thermal cycler.
RT-PCR
PCR reaction was performed using Premix Taq (Takara Ex Taq; Takara Korea Biomedical). Ten microliters of PCR premix, 1 mL downstream primer (10 pmol), 1 mL upstream primer (10 pmol), 1 mL reverse-transcribed cDNA, and RNase-free water were added to a total volume of 20 mL. PCR conditions were as follows: initial denaturation for 4 minutes at 94°C, followed by 30 cycles at 94°C, 57°C, and 72°C for 60, 60, and 50 seconds, respectively, with the final reaction at 72°C for 10 minutes. The sequence of the primer used here was a part of the human MISRII/AMHRII cDNA sequence (GenBank Accession No. AF172932), whereas the sense and antisense primers were 5 0 -TTTCCAGAGAGCTGTCCACG-3 0 (sequence 1612 to 1631) and 5 0 -GAGAAAGGGTACAGGCAGGC-3 0 (sequence 1758 to 1777), respectively. Following the PCR reaction, 20 mL of the obtained products was separated on a 1.5% agarose gel, and the product size (166 bp) was evaluated by a comparison with the DNA ladder. Densitometric analysis was performed using ImageJ software (version 1.48; National Institutes of Health, Bethesda, MD), and data for relative intensity were plotted as a histogram.
In situ hybridization
MISRII/AMHRII RNA probe (riboprobe) preparation
After obtaining 166 bp-sized cDNA molecules, they were inserted into the T Easy Vector system (Promega, Madison, WI), and subcloning was performed by the transformation of DH5a bacteria. The gene sequence and the appropriate direction of inserted cDNA were confirmed through the sequencing of the extracted plasmid. Antisense and sense riboprobes were prepared using NcoI and NotI treatments, respectively, and following this, the DIG DNA Labeling Kit (Boehringer Ingelheim GmbH, Mannheim, Germany) and SP6 and T7 polymerases were used to prepare antisense and sense riboprobes, respectively. After this initial preparation, the dotblot technique was used to determine whether the appropriate amount of riboprobes was prepared, and the riboprobes were further used for in situ hybridization analyses.
In situ hybridization
Wax sections (5 mm thick) were attached to the probes on the plus slide, and the wax was removed by ethanol. After drying them in an oven at 40°C for 1 hour, the sections were treated for 20 minutes in a solution containing 0.2 N HCl and pepsin (0.02 mg/mL). Afterward, they were washed with diethylpyrocarbonate-treated PBS and sequentially treated for 5 minutes each with 50%, 70%, 80%, 90%, and 100% ethanol and dehydrated and dried at 40°C for 1 hour. Hybridization solution, containing five times SSC, 10% Dextran sulfate, one times Denhardt solution, 50% formamide, and 1 mg/mL salmon sperm DNA, was prepared, and the samples were prehybridized for 2 hours at 58°C. For each 1000 mL of the hybridization solution, 200 ng RNA probes were incubated for 13 to 16 hours at 58°C oven. Following the hybridization, the slides were washed with Tris-buffered saline (TBS) and two, 0.5, and 0.2 times SSC, and afterward, they were soaked in normal swine serum (1:20) in TBS and treated for 30 minutes at room temperature. Subsequently, the samples were treated for 2 hours with alkaline phosphatase-conjugated anti-digoxigenin antibody (Boehringer Ingelheim GmbH), diluted to 1:400 in TBS, and the slides were washed three times with TBS for 10 min each time. Next, the slides were pretreated with detection buffer for 10 minutes, and color was allowed to develop in a darkroom, after a coloring solution containing 3.4 mL nitroblue tetrazolium and 3.5 mL 5-bromo-4-chloro-3-indolylphosphate (Boehringer Ingelheim GmbH) per 1 mL detection buffer, was applied to the slides.
Immunohistochemistry
MISRII/AMHRII antibody
The MISRII/AMHRII rabbit polyclonal antibody (153P) was generated by injecting animals with the kinase domain of the receptor expressed in Escherichia coli cells and was purified by histidine-affinity chromatography. The antibody was ligandaffinity purified before use. The specificity of this antibody for the MISRII/AMHRII was previously reported by Ha et al. (12) .
Immunohistochemistry
Immunohistochemistry of 5 mm-thick wax sections with ovarian and liver tissues was performed using the HistostainPlus kit (Thermo Fisher Scientific). In brief, the slides were blocked with peroxidase for 5 minutes and washed with TBS with 0.1% Tween-20 (T-TBS). Afterward, they were treated for 30 minutes with donkey serum (Thermo Fisher Scientific) and incubated overnight at 4°C with rabbit anti-human MISRII/ AMHRII polyclonal antibody (kindly provided by Professor Patricia K. Donahoe, Massachusetts General Hospital, Boston, MA). On the following day, the slides were washed three times for 10 minutes using T-TBS and incubated for 30 minutes at room temperature with the secondary antibody, biotinylated anti-rabbit IgG (Thermo Fisher Scientific). Again, the slides were washed with T-TBS and incubated for 30 minutes with the Streptavidin HRP Detection System (Thermo Fisher Scientific). After washing three times for 10 minutes with T-TBS, color reaction was induced with 0.1% 3,3-diaminobenzidine (Thermo Fisher Scientific) or 3-amino-9-ethylcarbazole, followed by hematoxylin counterstaining. The immunostained slides were sealed with glycerol gel for further analyses. Samples incubated without the addition of the primary antibody represented negative controls. The pre-embedding method, using 50 mm-thick vibratome sections, was also investigated, as described previously (13) . We analyzed three slides for each cell type and follicle.
Expression scoring system and statistical analysis
The intensity of immunohistochemistry staining was assessed independently by two pathologists. The frequencies of positively stained cells from five areas under a high magnification field were counted by percent. Frequency ,30% was classified as weakly positive, 30% to 60% as moderately positive, and .60% as strongly positive. Statistical comparisons between two experimental groups were performed using Student's t test (paired), whereas multiple group comparisons were performed using ANOVA. Data were regarded as being significant when P , 0.05.
Results
Intraovarian MISRII/AMHRII mRNA expression
RT-PCR analysis
We have detected bands at 166 bp in theca cell, granulosa cell, and testis samples, as was expected, with stronger expression of MISRII/AMHRII mRNA seen in the granulosa cells than in the theca cells. Sequencing of the obtained cDNAs confirmed that the sequence matched the human MISRII/AMHRII cDNA gene sequence (GenBank Accession No. AF172932; Fig. 2A ). The expression of MISRII/AMHRII mRNA in the granulosa cells (1 6 0.05) was stronger than that in the theca cells (0.48 6 0.06, P , 0.05). Although the expression of MISRII/AMHRII mRNA in granulosa cells was lower than in testis (1.35 6 0.32), there was no statistically significant difference (Fig. 2B) .
In situ hybridization
The flattened granulosa cells in primordial follicles failed to stain for MISRII/AMHRII mRNA, but the first staining was detected in the cuboidal granulosa cells in primary follicles. The granulosa cells of both single-and multiple-layered growing preantral follicles showed strong specific staining for MISRII/AMHRII mRNA, but theca cells showed weak staining (Fig. 3A) . In antral follicles, MISRII/AMHRII mRNA in situ signals were seen in both the granulosa cells and the theca cells, showing stronger expression in the granulosa cells than in the theca cells (Fig. 3B and 3C ). In the large antral follicle (Fig. 3D) , the atretic follicle (Fig. 3E) , and the corpus luteum (Fig. 3F) , MISRII/AMHRII mRNA staining of granulosa cells waned but was still detected weakly. However, the expression levels of MISRII/AMHRII mRNA in theca layers of these areas were lower than those in growing follicles. The MISRII/AMHRII mRNA staining was not found in primordial follicles, oocytes, interstitial cells, ovarian epithelium, and corpus albicans.
Intraovarian MISRII/AMHRII protein expression
Immunohistochemistry
The MISRII/AMHRII protein was expressed strongly in the granulosa cells (the frequency of expression, 78.11 6 10.67%) and very weakly in the theca cells of the preantral follicle (11.78 6 3.61%; Figs. 4A and 5). The granulosa cells and theca cells of small-and mediumsized antral follicle showed strong staining for MISRII/ AMHRII protein, although staining in the granulosa cells (72.11 6 10.96%) was more intense than that in the theca cells (33 (Fig. 4G ) and human liver specimen (Fig. 4H) , negative control for MISRII/ AMHRII protein, no immunoreactivity was detected.
Discussion
MIS/AMH is first produced in immature Sertoli cells in fetal testes, and it plays an important role in sexual development. In men, serum MIS/AMH can be measured in a concentration range of 10 to 70 ng/mL at birth, and its concentration increases gradually until puberty when it decreases to 2 to 5 ng/mL, and it is maintained at this range. In women, MIS/AMH expression in the ovary starts at the end of the third trimester of pregnancy, ;36 weeks of gestation, where it is produced by the fetal granulosa cells. MIS/AMH is detectable in women at birth and reaches the highest values after puberty. After the age of 18 years, the MIS/AMH level declines with age until 50 years. This pattern of age-dependent decrease indicates the pivotal effect of age on the ovarian reserve (3, 14, 15) .
MIS/AMH is involved in sex steroid synthesis and follicular development through the inhibition of aromatase production in the granulosa cells, luteinizing hormone receptor production, the proliferation of ovarian granulosa cells, and the production of progesterone (16, 17) . It may also affect the regulation of theca cell synthesis of androgens (18) . MIS/AMH production and activity are known to be regulated by estrogen and gonadotropin-releasing hormones, especially FSH (7, 19) . As MIS/AMH is no longer produced after menopause, its measurement can be used for the determination of the loss of ovarian functions (3, 15, 20) . Recently, several studies showed that MIS/AMH not only plays an important role in Müllerian duct regression but also inhibits growth of tumors originating from the Müllerian duct where the MISR/ AMHR is expressed, such as an endometrial cyst (21) and ovarian (12, 22) , cervical (23, 24) , and endometrial cancers (25, 26) .
MISR/AMHR, like other members of TGF-b family of receptors, is a heteromeric complex, comprised of type I and type II transmembrane serine/threonine kinase Figure 3 . Localization of MISRII/AMHRII mRNA expression in the (A) preantral, (B and C) small-and medium-sized antral, respectively, (D) large antral, and (E) atretic follicles and (F) corpus luteum using in situ hybridization. MISRII/AMHRII mRNA in situ signals of granulosa layers (G) were strong in the preantral and the small-and medium-sized antral follicles and waned in the large antral follicle, atretic follicle, and corpus luteum. Notice that MISRII/AMHRII mRNA in situ signals of theca layers (T) were detectable in all of the follicles and corpus luteum, with a higher level in the small-and medium-sized antral follicles. Original magnification: (A-C) 3230; (D) 3110; (E) 360; (F) 330. Insets in each panel represent two times magnification of the marked areas.
receptors. MISRII/AMHRII is 82 kDa in size and is composed of 573 amino acids (27) . However, MISRI/ AMHRI amino acid sequence has not been identified but is thought to be a 55-to 60-kDa activin receptor-like kinase (ALK), similar to the bone morphogenetic protein and GDP type I receptors of the TGF-b family. MIS/ AMH has been reported to affect target cells through a variety of type I receptors, such as ALK2, ALK3, or ALK6, depending on the type of cell (28) (29) (30) . MIS/AMH is cleaved into C-terminal and N-terminal dimers by proteases, such as plasmin and proprotein convertase 5, which is thought to be followed by C-terminal dimer binding to MISRII/AMHRII and subsequent MISRI/ AMHRI phosphorylation. The activated MISRI/AMHRI may phosphorylate receptor-specific cytoplasmic proteins, such as mothers against decapentaplegic homolog (SMAD) 1, SMAD5, or SMAD8, after which the phosphorylated SMADs bind to transcriptional activator SMAD4, which enters the nucleus and binds the promoter of target genes with the help of a coactivator, SMAD-associated factor, triggering transcription (5, 6).
Baarends et al. (31) , who first reported MISRII/ AMHRII mRNA expression in rat ovaries, suggested that in rodents, unlike MIS/AMH, which is differentially expressed in men and women, MISRII/AMHRII is expressed in Müllerian mesenchymal cells and the gonads of both men and women. Furthermore, the expression of MISRII/AMHRII in murine ovaries after birth was shown to follow a pattern similar to MIS/AMH expression, suggesting an autocrine activity. Additionally, MISR/AMHR was detected only in the granulosa cells of growing follicles, such as preantral and small antral follicles, and was not detected in theca cells, oocytes, or ovarian stroma or cortex (7) . However, in the adult rat ovaries, MISRII/AMHRII was expressed in both granulosa and theca cells of the preantral and small antral follicles, but unlike the granulosa cell expression, theca cells continued to express MISRII/AMHRII in antral and early atretic follicles (9, 10) . The present data also demonstrate that the MISRII/AMHRII in the human is expressed in both granulosa and theca cells of the preantral and antral follicles, with continued but demanding expression in the theca cells in early atretic follicles and corpus luteum. Grøndahl et al. (32) showed that mural granulosa cells differ from cumulus granulosa cells that are more likely to express MIS/AMH in the preovulatory follicle. In human preovulatory follicles, MISRII/AMHRII mRNAs are expressed more in cumulus cells than in mural cells. In our study samples, there were no slides containing cumulus granulosa cells; therefore, we could not compare mural and cumulus granulosa cells. Additionally, the focus of our investigation was not granulosa cells but theca cells.
The expression patterns of MIS/AMH and MISRII/ AMHRII indicate that MIS/AMH may play an important role in ovarian folliculogenesis (33) . Durlinger et al. (34) used murine mouse ovaries to show that the role of MIS/ AMH, produced in the granulosa cells, causes inhibition of initial follicular development via paracrine activity on primordial follicles. In men, MIS/AMH is produced in Sertoli cells and affects steroidogenesis in Leydig cells through autocrine and paracrine actions (35, 36) . As in men, MIS/AMH in women has a paracrine regulation on steroidogenesis in theca cells. Theca cells are important in synthesis of androgen, which is modulated by several factors, such as insulin-like growth factor, insulin, TGF-b superfamily members, and their related pathways and regulators (18) . MISRII/AMHRII may prove to be yet another modulator of theca cells, given its expression pattern, albeit low. Dewailly and colleagues (4) suggested that MIS/AMH not only suppresses initial follicular recruitment but also FSH-dependent follicular growth and selection of preantral and small antral follicles.
However, most of the studies investigating MIS/AMH and MISR/AMHR to date were performed in vitro, and most in vivo experiments have been performed using rodents, whereas human studies, examining the expression of MISR/AMHR in women of childbearing age have not before been conducted. MISRII/AMHRII expression in theca cells has been especially controversial. Therefore, studies, such as this, using human ovary samples, may help further our understanding of MIS/AMH in the ovary. Additionally, not only the expression level of MIS/ AMHRII but also the serum and follicular level of MIS/ AMH could affect the function of MIS/AMH. However, we did not check circulating and follicular MIS/AMH levels in this study. Because our study was focused on morphological analysis, we did not check these profiles.
Here, we have demonstrated that MISRII/AMHRII mRNA in the human is expressed in both granulosa and theca cells using laser microdissection, followed by RT-PCR. This was additionally verified using in situ hybridization and immunohistochemistry. A high level of MISRII/AMHRII mRNA and protein expression was detected in granulosa cells of preantral and antral follicles, but its expression levels were lower in theca cells. Unlike the granulosa cell expression, the theca cells continued to express MISRII/AMHRII in early atretic follicles and corpus luteum. The expression patterns between MISRII/AMHRII mRNA and protein are similar in ovaries, except in both atretic follicle and corpus luteum, where granulosa cell expression disappears, but theca cell production perdures but diminishes.
In conclusion, here, we showed that MISRII/AMHRII is expressed in human ovaries, not only in granulosa but in theca cells as well. Therefore, this finding suggests that MIS/AMH, produced in the ovarian granulosa cells, acts through the intraovarian autocrine mechanism, in addition to the paracrine mechanism. Future studies investigating MISR/AMHR should provide further understanding of the mechanisms of MIS/AMH involved in both folliculogenesis and steroidogenesis.
